Hyperphagia is a condition marked by an intense, uncontrollable sensation of hunger that persists even after eating. For those living with this condition, everyday meals do not bring the expected feeling of fullness or satisfaction. Instead, the drive to consume food remains constant, often leading to serious health challenges and requiring careful, ongoing management tailored to each individual’s needs.

Understanding the Challenge of Persistent Hunger

When most people finish a meal, they experience a sense of satisfaction that naturally reduces their interest in food for several hours. However, individuals with hyperphagia—sometimes also referred to as polyphagia—face a very different reality. This condition involves an extreme, persistent feeling of hunger that does not go away after eating, no matter how much food is consumed.^[1] The word “hyperphagia” comes from medical terminology describing excessive eating accompanied by an overwhelming focus on food, and it differs significantly from the temporary increase in appetite that anyone might feel after vigorous exercise or a long day of physical work.^[2]

People with hyperphagia often describe their experience as feeling hungry all the time, with a constant preoccupation with food and eating. This sensation does not resolve with typical eating patterns. Instead, the hunger is relentless, driving behaviors that can include sneaking or stealing food, eating items that would normally be considered unacceptable (such as food scraps or partially spoiled items), and experiencing significant distress around meal times and food availability.^[2] The lack of normal satiety—the feeling of fullness that signals the body has had enough to eat—is a hallmark of this condition.^[2]

The goals of managing hyperphagia center on helping individuals control their intense hunger, prevent excessive weight gain and related health complications, and improve overall quality of life. Treatment approaches depend heavily on the underlying cause of the hyperphagia, whether it stems from a genetic syndrome, a metabolic disorder, hormonal imbalance, or another medical condition.^[1] Each person’s experience with hyperphagia is unique, making individualized care essential. Some people may experience hyperphagia as a constant, powerful hunger drive, while others may notice it more as an obsession with food, a need for constant reassurance about when the next meal will occur, or difficulty ever feeling satisfied after eating.^[2]

What Causes Hyperphagia

Hyperphagia can arise from a wide range of underlying conditions. Understanding the root cause is crucial because it guides how the condition is treated. One of the most recognized causes is Prader-Willi syndrome (PWS), a rare genetic disorder caused by the absence of certain genes on chromosome 15. This syndrome is particularly well-known for producing severe hyperphagia, often starting in early childhood and continuing throughout life.^[2][3] Babies with Prader-Willi syndrome typically begin life with poor muscle tone and little interest in food, sometimes experiencing failure to thrive. However, this phase is followed by a dramatic shift, usually occurring around age 8 on average, though it can begin as early as 2 years or as late as the teenage years, when intense hyperphagia develops.^[2]

Metabolic and hormonal conditions also commonly trigger hyperphagia. Diabetes is a frequent culprit. When the body cannot properly use insulin—a hormone that allows cells to take in glucose from the blood—glucose builds up in the bloodstream but cannot be used for energy. The body interprets this lack of usable energy as starvation, triggering intense hunger.^[4][12] This can occur in Type 1 diabetes, Type 2 diabetes, and gestational diabetes. In Type 1 diabetes, the body produces little or no insulin, and the intense hunger is often accompanied by rapid weight loss as the body breaks down fat and muscle for fuel. In Type 2 diabetes, cells become resistant to insulin, and although hyperphagia may be present, it is often less dramatic.^[12]

Another hormonal cause is hyperthyroidism, a condition in which the thyroid gland produces too much thyroid hormone. These hormones control the body’s metabolism—the rate at which the body uses energy. When thyroid hormones are excessive, metabolism speeds up dramatically, burning through energy stores quickly and triggering increased appetite and hunger.^[4] Hypoglycemia, or low blood sugar, can also cause intense hunger. When blood sugar drops below normal levels, the body urgently signals the need for more fuel, resulting in shakiness, dizziness, sweating, and powerful hunger.^[4][12]

Beyond genetic and metabolic causes, hyperphagia can be influenced by lifestyle factors. Lack of sleep is a well-documented contributor. When people do not get enough quality sleep, their bodies struggle to regulate hormones that control hunger, such as ghrelin (which stimulates appetite) and leptin (which signals fullness). Sleep deprivation can increase levels of cortisol, a stress hormone that also stimulates appetite.^[4] Chronic stress itself can trigger hyperphagia, as elevated cortisol levels drive the body to seek more food, especially high-calorie, comforting foods.^[4]

Certain medications, including corticosteroids and some antidepressants, are known to increase appetite significantly.^[6][12] Hormonal fluctuations related to the menstrual cycle can also cause increased hunger, particularly in the days leading up to menstruation, a phenomenon known as premenstrual syndrome (PMS).^[4] Additionally, rare genetic mutations affecting pathways such as the melanocortin 4 receptor (MC4R) pathway, which plays a key role in regulating appetite and energy balance, can lead to hyperphagia and severe obesity.^[9]

Standard Approaches to Managing Hyperphagia

Managing hyperphagia begins with identifying and addressing the underlying cause. For individuals whose hyperphagia is related to diabetes, the primary goal is to stabilize blood sugar levels through insulin therapy or other diabetes medications, alongside dietary management and regular physical activity. Controlling blood glucose levels can significantly reduce the intense hunger that characterizes diabetic hyperphagia.^[12] If hyperthyroidism is the cause, treatments such as antithyroid medications, radioactive iodine therapy, or surgery to remove part of the thyroid gland may be used to normalize thyroid hormone levels and, in turn, reduce excessive hunger.^[4]

For people with Prader-Willi syndrome, management is highly specialized and lifelong. Because there is no cure for PWS, treatment focuses on controlling the symptoms of hyperphagia and preventing obesity and its complications. This requires a structured, highly controlled environment in which access to food is strictly limited. Families and caregivers must lock kitchens, pantries, and refrigerators, plan all meals and snacks in advance, and supervise individuals with PWS constantly to prevent unauthorized eating.^[2][13] This level of environmental control is demanding, but it is necessary to prevent life-threatening complications such as choking, stomach rupture, and severe obesity.

Nutritional counseling is a cornerstone of hyperphagia management across all causes. Working with a registered dietitian, individuals can develop meal plans that emphasize nutrient-dense, lower-calorie foods that promote a feeling of fullness. High-fiber foods, lean proteins, and foods with high water content (such as vegetables and fruits) can help increase satiety.^[13] Portion control and regular meal timing are also important strategies. In some cases, dietary supplements or meal replacement products may be used under medical supervision to ensure adequate nutrition while controlling calorie intake.

Behavioral interventions and psychological support play an essential role. Cognitive-behavioral therapy (CBT) and other forms of counseling can help individuals develop coping strategies for managing food cravings, emotional eating, and the distress associated with constant hunger. Support groups and peer networks provide emotional support and practical advice, particularly for families dealing with genetic syndromes like Prader-Willi syndrome.^[1] For individuals whose hyperphagia is related to stress, mental health counseling and stress management techniques such as mindfulness, meditation, and relaxation exercises may help reduce the hormonal drive to overeat.

Medications that affect appetite and metabolism are sometimes used to manage hyperphagia, depending on the underlying cause. For example, medications that improve insulin sensitivity or regulate blood sugar can help reduce hunger in people with diabetes. In some cases, appetite-suppressing medications may be considered, though these must be carefully monitored for side effects and effectiveness.^[13] Hormone replacement therapies, particularly growth hormone therapy, are commonly used in individuals with Prader-Willi syndrome to improve body composition, increase muscle mass, and reduce fat mass, although growth hormone does not directly reduce hyperphagia.^[13]

In individuals with severe obesity caused by hyperphagia who have not responded to other treatments, bariatric surgery (weight-loss surgery) may be considered. However, surgery is a complex decision and carries risks, particularly in people with genetic syndromes or metabolic disorders. The benefits and risks must be carefully weighed, and surgery is typically reserved for cases where other interventions have failed.^[13]

Emerging Treatments Being Studied in Clinical Trials

Research into new treatments for hyperphagia is advancing rapidly, offering hope for individuals who struggle with current management strategies. Clinical trials are testing a range of innovative therapies, from new medications to advanced biological approaches. Many of these trials focus on Prader-Willi syndrome, given the severity of hyperphagia in this condition, but the findings may have broader applications for other causes of hyperphagia as well.^[1]

One of the most significant recent developments is the FDA approval of VYKAT XR (diazoxide choline extended-release tablets), the first medication approved specifically to treat hyperphagia in people with Prader-Willi syndrome. This approval, which occurred in March 2025, marks a major milestone for the PWS community.^[11][14] VYKAT XR works through a mechanism that is not fully understood but is believed to involve effects on insulin secretion and energy metabolism. In clinical trials, individuals who took VYKAT XR showed significant improvements in hyperphagia symptoms compared to those who received a placebo. The medication was tested in a Phase III randomized withdrawal trial, where participants who had been taking the drug for an average of 3.3 years were either continued on treatment or switched to placebo. Those who switched to placebo experienced a worsening of hyperphagia, demonstrating the drug’s effectiveness.^[11] VYKAT XR became available in the United States in April 2025, and the company behind it has established patient support programs to help families access the treatment.^[11][14]

Other medications being explored in clinical trials include drugs that target the melanocortin 4 receptor (MC4R) pathway. The MC4R pathway is a key regulator of hunger and energy balance in the brain. Genetic defects in this pathway can cause severe obesity and hyperphagia. MC4R agonists—medications that activate this receptor—are being tested to see if they can reduce hunger and promote weight loss in people with genetic obesity syndromes.^[9][10] These drugs aim to mimic the natural signals that tell the brain the body has had enough to eat. Early-phase trials are assessing the safety and effectiveness of these compounds, with some showing promising results in reducing appetite and body weight.

Hormone-based therapies are another area of active research. One such approach involves intranasal oxytocin, a hormone that plays a role in social bonding and has been shown in some studies to reduce food intake and food-seeking behaviors in people with Prader-Willi syndrome. Clinical trials have tested oxytocin delivered as a nasal spray, with mixed but generally encouraging results. Some studies found modest reductions in hyperphagia and improvements in social behaviors, though more research is needed to confirm these effects and determine the optimal dosing.^[13]

GLP-1 receptor agonists are another class of drugs being investigated. These medications, which include drugs like semaglutide and liraglutide, are already approved for treating Type 2 diabetes and obesity in the general population. They work by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which is released by the intestines after eating and signals the brain to reduce appetite and slow stomach emptying. Researchers are now studying whether GLP-1 agonists can help reduce hyperphagia in people with Prader-Willi syndrome and other genetic obesity syndromes. Early clinical experience suggests these drugs may help some individuals, though they do not work for everyone and side effects such as nausea and vomiting can be problematic.^[10][13]

Gene therapy and other advanced biological approaches are on the horizon. Scientists are exploring the possibility of using gene editing or gene replacement therapies to correct the underlying genetic defects that cause Prader-Willi syndrome and other genetic forms of hyperphagia. These approaches are still in early research stages and have not yet reached clinical trials in humans, but they represent a potential future direction for curative treatments.^[1]

Clinical trials for hyperphagia treatments are conducted in multiple phases. Phase I trials test a new drug or therapy in a small group of people to evaluate its safety, determine a safe dosage range, and identify side effects. Phase II trials involve a larger group of participants and focus on assessing the drug’s effectiveness and further evaluating its safety. Phase III trials compare the new treatment to standard treatments or a placebo in even larger groups of people, providing more definitive evidence of effectiveness and monitoring side effects. Once a drug successfully completes Phase III trials and is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA), it can be prescribed to patients.^[11]

Many of these clinical trials are conducted at specialized research centers in the United States, Europe, and other regions. Eligibility criteria vary depending on the specific trial, but generally include factors such as age, diagnosis, severity of hyperphagia, and overall health. Families and individuals interested in participating in clinical trials for hyperphagia can speak with their healthcare providers or search clinical trial registries to find opportunities that may be appropriate for them.^[1]

Most Common Treatment Methods

• Environmental and Behavioral Control
  • Strict supervision and limitation of access to food, including locking kitchens and food storage areas, particularly critical in Prader-Willi syndrome management
  • Structured meal and snack schedules with pre-planned portion sizes
  • Cognitive-behavioral therapy and counseling to develop coping strategies for managing food cravings and emotional distress
  • Family education and support programs to help caregivers manage the challenges of hyperphagia
• Medical Management of Underlying Conditions
  • Insulin therapy and blood glucose monitoring for diabetes-related hyperphagia
  • Antithyroid medications, radioactive iodine, or surgery for hyperthyroidism
  • Medication adjustments if hyperphagia is triggered by drugs like corticosteroids or antidepressants
  • Hormone replacement therapies, including growth hormone therapy in Prader-Willi syndrome to improve body composition
• Nutritional Interventions
  • Individualized meal planning with registered dietitians, emphasizing high-fiber, high-protein, nutrient-dense foods
  • Portion control strategies and use of lower-calorie, high-volume foods to promote satiety
  • Dietary supplements or meal replacements under medical supervision when appropriate
• Pharmacological Treatments
  • VYKAT XR (diazoxide choline extended-release), the first FDA-approved medication for hyperphagia in Prader-Willi syndrome
  • GLP-1 receptor agonists (such as semaglutide and liraglutide) being studied for their appetite-suppressing effects
  • MC4R agonists and other investigational drugs targeting brain pathways that regulate hunger and satiety
  • Intranasal oxytocin being tested in clinical trials for reducing food-seeking behaviors
• Surgical and Advanced Interventions
  • Bariatric surgery considered in selected cases of severe obesity unresponsive to other treatments
  • Gene therapy and gene editing approaches being explored in early research for genetic causes of hyperphagia

Living with Hyperphagia: Ongoing Challenges and Support

Living with hyperphagia presents daily challenges that extend far beyond simple hunger. For individuals with the condition, the constant preoccupation with food can dominate thoughts, affect relationships, and limit independence. For caregivers and family members, the burden of constant vigilance, food security measures, and emotional support can be exhausting and stressful. The intensity of hyperphagia can vary over time, sometimes worsening in response to changes in routine, stress, or other environmental factors.^[2]

Support networks are invaluable for families and individuals coping with hyperphagia. Organizations dedicated to Prader-Willi syndrome and other genetic obesity syndromes offer educational resources, advocacy, and opportunities to connect with others facing similar challenges. These groups provide a sense of community and shared understanding that can be profoundly helpful. Healthcare teams that include physicians, dietitians, mental health professionals, and social workers working together provide the most comprehensive and effective care.^[1]

As research continues and new treatments become available, there is growing optimism that better management options will emerge. The approval of VYKAT XR represents a significant step forward, demonstrating that targeted therapies for hyperphagia are possible. Ongoing clinical trials hold the promise of additional medications and interventions that may further improve outcomes and quality of life for people living with this challenging condition.^[11][14]